Trial Profile

A Phase 1b/2a Randomized, Blinded, Placebo-controlled Study in Participants With Mild to Moderate COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Orally Administered ProLectin-M

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 May 2025 According to a BioXyTran media release, company is to submit to FDA/CDSCO for additional pivotal trials.
12 May 2025 According to a BioXyTran media release, company announced the successful completion of the dose optimization of its antiviral drug ProLectin-M. Preliminary results are expected, with full data submission to the FDA under Bioxytrans active Investigational New Drug (IND) clinical trials for ProLectin-M.
21 Feb 2024 Status changed from not yet recruiting to recruiting, according to a BioXyTran media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com